Trial Profile
Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary) ; Nivolumab (Primary)
- Indications Glioma; Solid tumours
- Focus Therapeutic Use
- 30 Nov 2023 Status changed from recruiting to completed.
- 26 Jun 2023 Planned End Date changed from 1 May 2026 to 31 May 2026.
- 26 Jun 2023 Planned primary completion date changed from 1 Mar 2024 to 31 Mar 2024.